BRCA2 and ovarian neoplasm: PARP inhibitors such as olaparib and pamiparib have been demonstrated to be indicative of monotherapy in patients with ovarian tumor harboring BRCA1 or BRCA2 mutations (Ledermann, 2016; Markham, 2021).